Ghana COVID-19 Vaccinations and Financial Incentives

How to cite

Duch, Raymond. 2022. "Ghana COVID-19 Vaccinations and Financial Incentives." AEA RCT Registry. AEARCTR-0008775. https://doi.org/10.1257/rct.8775-3.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Raymond Duch*

* Primary investigator

Registry ID
AEARCTR-0008775
DOI
https://doi.org/10.1257/rct.8775-3.0
First registered
Last updated
Status
Completed
Trial dates
2022-02-05 – 2022-04-30
Countries
Ghana (Africa)
JEL codes
D78, H41, I18
Registry record
http://www.socialscienceregistry.org/trials/8775

Abstract

Achieving global vaccination against COVID-19 is a critical worldwide challenge. While COVAX is planning mass vaccination of Africa in 2022, there are substantial challenges. Cash incentives have been proposed as a way to improve the efficiency and equity of the roll-out in Africa. Recent experimental evidence suggests that financial incentives can promote the adoption of preventive health habits (Hussam etal 2022) and more specifically vaccine uptake (Campos Mercade etal 2021). To evaluate whether cash incentives affect the willingness to get the COVID-19 vaccine, we are undertaking a field experiment, designed and conducted in consultation with the University of Ghana and the Ghana Health Service. The experiment will evaluate the impact of cash incentives on vaccine uptake.

Intervention

The experiment has four treatments that are delivered in a short video:

Treatment 1: A placebo video that provides general information about the benefit of using solar power to charge household electrical appliances.

Treatment 2: Standard CDC COVID-19 vaccine promotional and information video.

Treatment 3: Low Cash Incentive treatment -- the first 30 seconds are identical to the CDC video -- the last 15 seconds inform viewers that that they will earn $3 if they provide proof of a COVID-19 vaccine within the next 6 weeks.

Treatment 4: High Cash Incentive treatment -- the first 30 seconds are identical to the CDC video -- the last 15 seconds inform viewers that that they will earn $10 if they provide proof of a COVID-19 vaccine within the next 6 weeks.

Experimental design

The randomized control trial is designed to measure the direct impact of financial incentives on individual vaccine update rates in the Ghana rural population. The clustered randomized control trial will randomly select 6,552 participants from selected rural households; in 312. villages and from 6 Ghana Districts. We adopted a cluster random assignment design in order to address spillover effects that could have important implications for evaluating the overall benefits (and costs) of implementing financial incentives for vaccine uptake.

Village clusters are randomly assigned to receive on of four video treatment arms: a placebo, a standard health message, a high cash incentive ($10) and a low cash incentive ($3). Randomly selected participants within a village will be assigned to one of the four video treatment arms. In addition, a proportion of subjects (25 percent) within village clusters assigned to one of the three treatment arms receive the placebo treatment. We incorporate placebo treatments in the design in order to facilitate the identification of both direct and indirect treatment effects that are decoupled from the delivery mechanism.

Design details

Randomization method
Villages are randomly selected from population ranked quadruples by a computerized random number generated. Households are randomly selected by random walk instructions. Individuals within households are randomly selected by a coin flip.
Randomization unit
Villages, households and individuals within households
Clusters
312 Village clusters.
Observations
6,500 individuals
Arms
1,625
Primary outcomes
The outcome variable is whether subjects received a COVID-19 vaccine after the initial video intervention. We will begin measuring the outcome for all 6,000 subjects after the six-week reporting period for the Low and High Cash treated subjects. We expect this to begin in approximately one week after the six-week deadline for Low and High cash subjects to indicate whether they had been vaccinated.
Secondary outcomes
We explicitly incorporate design features that will allow us to estimate the spillover effect of the video treatments -- non-treated experimental subjects who are affected indirectly by the COVID-19 video treatments.

Materials

Papers from this trial

  1. @Article{Duchetal2023, author={Duch, Raymond and Asiedu, Edward and Nakamura, Ryota and Rouyard, Thomas and Mayol, Alberto and Barnett, Adrian and Roope, Laurence and Violato, Mara and Sowah, Dorcas and Kotlarz, Piotr and Clarke, Philip}, title={Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial}, journal={Nature Medicine}, year={2023}, month={Dec}, day={01}, volume={29}, number={12}, pages={3193-3202}, abstract={We implemented a clustered randomized controlled trial with 6,963 residents in six rural Ghana districts to estimate the causal impact of financial incentives on coronavirus disease 2019 (COVID-19) vaccination uptake. Villages randomly received one of four video treatment arms: a placebo, a standard health message, a high cash incentive (60 Ghana cedis) and a low cash incentive (20 Ghana cedis). For the first co-primary outcome---COVID-19 vaccination intentions---non-vaccinated participants assigned to the cash incentive treatments had an average rate of 81{\%} (1,733 of 2,168) compared to 71{\%} (1,895 of 2,669) for those in the placebo treatment arm. For the other co-primary outcome of self-reported vaccinations 2{\thinspace}months after the initial intervention, the average rate for participants in the cash treatment was 3.5{\%} higher than for participants in the placebo treatment (95{\%} confidence interval (CI): 0.001, 6.9; P{\thinspace}={\thinspace}0.045): 40{\%} (602 of 1,486) versus 36.3{\%} (672 of 1,850). We also verified vaccination status of participants: in the cash treatment arm, 36.6{\%} (355 of 1,058) of verified participants had at least one dose of the COVID-19 vaccine compared to 30.3{\%} (439 of 1,544) for those in the placebo---a difference of 6.3{\%} (95{\%} CI: 2.4, 10.2; P{\thinspace}={\thinspace}0.001). For the intention and the vaccination outcomes, the low cash incentive (20 Ghana cedis) had a larger positive effect on COVID-19 vaccine uptake than the high cash incentive (60 Ghana cedis). Trial identifier: AEARCTR-0008775.}, issn={1546-170X}, doi={10.1038/s41591-023-02670-4}} https://doi.org/10.1038/s41591-023-02670-4

Cited by

No citation data available for this registration yet.

Keywords